PENTA 13

A Model-based approach to dose selection in early pediatric development

19 Apr, 2010

Authors: Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O. Published in: Clinical Pharmacology and Therapeutics, 2010, 87(3):294-302. Abstract The establishment of a rationale for determining…
Read More

Adherence and acceptability of once daily lamivudine and abacavir in HIV-1 infected children

19 Apr, 2006

Authors: LeProvost M, Green H, Flynn J, et al; on behalf of the PENTA 13 study group. Published in: Pediatr Infect Dis J. 2006;25(6):533-7 Background Data on adherence to and…
Read More

Adherence and acceptability of once daily lamivudine and abacavir in HIV-1 infected children

19 Jul, 2005

Authors: LeProvost M, Green H, Flynn J, et al: on behalf of the PENTA 13 study group. Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005,…
Read More

Pharmacokinetics of once versus twice daily lamivudine and abacavir. Simplification of combination treatment in HIV-1 infected children (Penta 13)

19 Apr, 2005

Authors: Bergshoeff A, Burger D, Verweij C, et al; on behalf of the PENTA 13 study group Published in: Antivir Ther. 2005; 10:239-246 Background There are few data on plasma and intracellular pharmacokinetics (PK)…
Read More

Pharmacokinetics (PK) of once daily versus twice daily Lamivudine and Abacavir in HIV-1 infected children: PENTA 13

19 Feb, 2004

Authors: Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Gibb DM. Published in: 11th Conference of Retroviruses and Opportunistic Infections,…
Read More